{"filing":{"accession_number":"0001140361-26-025614","cik":"0001506492","ticker":"NUWE","company_name":"Nuwellis, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"ef20076374_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036126025614/ef20076374_8k.htm"},"events":[{"id":11666,"run_id":10249,"accession_number":"0001140361-26-025614","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Michael McCormick was appointed Chief Executive Officer and President of Nuwellis, Inc., effective June 30, 2026, and elected to the Board. John L. Erb transitioned from CEO to Chairman. McCormick brings extensive executive experience in medical device companies.","company_name":"Nuwellis, Inc.","ticker":"NUWE","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8312,"accession_number":"0001140361-26-025614","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Michael McCormick as Chief Executive Officer and President effective June 30, 2026, along with his election to the Board. While John L. Erb's resignation as CEO is also mentioned, the principal action disclosed is McCormick's appointment to the CEO role. The filing emphasizes McCormick's extensive executive background in medical device companies and his qualifications for leading the company forward, making the appointment the salient event. This is material as CEO changes significantly affect investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T10:01:15.709626+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8313,"accession_number":"0001140361-26-025614","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Mike McCormick as Chief Executive Officer, effective June 30, 2026, replacing John Erb who transitions to Chairman. This is a material executive appointment of a C-suite officer at a public company, disclosed via press release in Item 7.01 (Regulation FD Disclosure). While Erb's departure from the CEO role is also disclosed, the principal action centers on McCormick's appointment to lead the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T10:01:15.709626+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8312,"accession_number":"0001140361-26-025614","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Michael McCormick as Chief Executive Officer and President effective June 30, 2026, along with his election to the Board. While John L. Erb's resignation as CEO is also mentioned, the principal action disclosed is McCormick's appointment to the CEO role. The filing emphasizes McCormick's extensive executive background in medical device companies and his qualifications for leading the company forward, making the appointment the salient event. This is material as CEO changes significantly affect investor assessment of company leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T10:01:15.709626+00:00","company_name":"Nuwellis, Inc.","ticker":"NUWE","filing_date":"2026-06-17"},{"id":8313,"accession_number":"0001140361-26-025614","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing announces the appointment of Mike McCormick as Chief Executive Officer, effective June 30, 2026, replacing John Erb who transitions to Chairman. This is a material executive appointment of a C-suite officer at a public company, disclosed via press release in Item 7.01 (Regulation FD Disclosure). While Erb's departure from the CEO role is also disclosed, the principal action centers on McCormick's appointment to lead the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T10:01:15.709626+00:00","company_name":"Nuwellis, Inc.","ticker":"NUWE","filing_date":"2026-06-17"}]}